Calder Thomas, Tong Tina, Hu Dale J, Kim Jerome H, Kotloff Karen L, Koup Richard A, Marovich Mary A, McElrath M Juliana, Read Sarah W, Robb Merlin L, Renzullo Philip O, D'Souza M Patricia
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
International Vaccine Institute, Seoul, Republic of Korea.
Commun Med (Lond). 2022 Aug 29;2:110. doi: 10.1038/s43856-022-00175-8. eCollection 2022.
The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.
新型冠状病毒肺炎（COVID-19）疫苗的迅速研发及其在不到一年的时间内投入使用，是一项前所未有的科学、医学和公共卫生成就。这一快速发展利用了数十年来在人类免疫缺陷病毒/获得性免疫综合征（HIV/AIDS）研究中积累的知识和取得的进展。然而，寻找一种有助于持久终结HIV大流行的HIV疫苗仍然难以实现。在此，我们借鉴美国政府的经验，强调从COVID-19疫苗研发中吸取的教训，包括公私伙伴关系的重要性、公平纳入受传染性病原体影响的人群，以及持续对基础研究的投入。我们总结了为加快和重振安全有效的HIV疫苗研发框架而需考虑的关键因素。
